(AOF) – GenSight Biologics (-5.89% to 0.39 euros) announces that its cash position stands at 2.2 million euros as of March 31, 2024, compared to 2.1 million euros as of December 31, 2023 The biotech specialist in innovative gene therapies for neurodegenerative diseases of the retina and central nervous system disorders warns that it does not have sufficient net working capital to meet its obligations over the next 12 months, but “only until the end of April 2024”.
Gensight says it is currently engaged in active discussions to secure funding for its activities until the 3rd quarter of 2024, when the Early Access Program (EAP) in France is expected to resume. Upon resumption of this program, the biotech estimates that its cash flow horizon will be extended until the end of the first quarter of 2025.
The company is also engaged in numerous discussions on strategic opportunities with potential partners, including a possible merger, acquisition or licensing agreement,
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.